BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21311411)

  • 1. The role of inosine-5'-monophosphate dehydrogenase in thiopurine metabolism in patients with inflammatory bowel disease.
    Haglund S; Vikingsson S; Söderman J; Hindorf U; Grännö C; Danelius M; Coulthard S; Peterson C; Almer S
    Ther Drug Monit; 2011 Apr; 33(2):200-8. PubMed ID: 21311411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
    Haglund S; Taipalensuu J; Peterson C; Almer S
    Br J Clin Pharmacol; 2008 Jan; 65(1):69-77. PubMed ID: 17662091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
    Hindorf U; Jahed K; Bergquist A; Verbaan H; Prytz H; Wallerstedt S; Werner M; Olsson R; Björnsson E; Peterson C; Almer SH
    J Hepatol; 2010 Jan; 52(1):106-11. PubMed ID: 19906459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.
    Chouchana L; Narjoz C; Roche D; Golmard JL; Pineau B; Chatellier G; Beaune P; Loriot MA
    Pharmacogenomics; 2014 Apr; 15(6):745-57. PubMed ID: 24897283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
    Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
    Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITPA Activity in Adults and Children Treated With or Without Azathioprine: Relationship Between TPMT Activity, Thiopurine Metabolites, and Co-medications.
    Citterio-Quentin A; Moulsma M; Gustin MP; Boulieu R
    Ther Drug Monit; 2017 Oct; 39(5):483-491. PubMed ID: 28650902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of inosine 5'-monophosphate dehydrogenase activity in red blood cells of thiopurine-treated patients using HPLC.
    Beringer A; Citterio-Quentin A; Otero RO; Gustin C; Clarke R; Salvi JP; Boulieu R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Feb; 1044-1045():194-199. PubMed ID: 28110955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
    Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
    Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.